GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market.

A year after GSK pulled its BCMA-targeting antibody-drug conjugate (ADC) Blenrep from the US market as a later-line therapy for multiple myeloma, there are signs that the drug may still have a ...

The structure of a small molecule can also be shown as a three-dimensional ball-and-stick model. These models show how the atoms and bonds are arranged in space. The diagram shows a ball-and-stick ...